PRINCETON, NJ – Sept. 13, 2018 – Certara announced today that it has acquired Pirana, a widely used product for connecting and organizing pharmacometric modeling results as well as providing interfaces to a range of software tools used in pharmacometrics modeling.
Duchenne Muscular Dystrophy (DMD) is a life-threatening, sex-linked, pediatric rare disease, primarily affecting boys. It is characterized by progressive muscle degeneration, weakness, and eventually functional loss. DMD is caused by a mutation in the dystrophin gene, a protein needed to maintain muscle integrity, and for improving signaling and growth in differentiation of the muscle tissue. […]
This webinar focused on the impact of RI on substrates of organic cation transporter 2 (OCT2), one of the major renal transporters which has been shown to be affected—both in activity and expression—in RI in pre-clinical species and in vitro systems.
PRINCETON, NJ – Sept. 5, 2018 – Certara today announced that it has appointed Mark Holbrook, PhD, to the newly-created position of vice president of quantitative systems toxicology and safety (QSTS).
In vitro in vivo correlation (IVIVC) links in vitro drug data to in vivo performance. Regarding in vivo performance, IVIVC can predict either the in vivo plasma time-concentration curve or in vivo pharmacokinetic (PK) parameters like Cmax and AUC. In this blog, I will discuss Level C IVIVC, and when you should use this approach. […]
The impact of MIDD is especially powerful in oncology, where numerous cases demonstrate its enormous value in streamlining and accelerating the development cycle and supporting breakthrough therapy options for these fragile patients.
Certara’s D360 Version 10.5 Extends Platform’s Ability to Optimize Discovery Research Across Therapeutic Modalities
August 16, 2018 – Certara today announced the launch of D360 v10.5, the first in a series of releases focused on delivering biologic-relevant tools together with D360’s data access capabilities.